Epilepsy News and Research

Latest Epilepsy News and Research

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

Researchers find two high-fat diets reduce absence epilepsy in children

Two high-fat diets the classic ketogenic and a modified version of the Atkins can reduce and, in some cases, completely eliminate seizures in children with a common seizure disorder known as absence epilepsy, say researchers from Johns Hopkins Children's Center.

27 Aug 2010

NSW bed sore death could have been prevented: Coroner

After the death of a severely disabled woman in New South Wales, the coroner has ruled that the death due to bed sores was avoidable and caregivers need more training to manage such cases. 26-year-old Kate Therese Bugmy died at Broken Hill Base Hospital in June 2007 as a result of sepsis from bed sores. She had severe cerebral palsy, epilepsy and an intellectual disability and weighed just 36 kilos when she died.

26 Aug 2010

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer's disease, according to new research published in the August 25, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2010

Cyberonics reports 16% increase in net sales for first quarter 2011

Cyberonics, Inc. today announced results for the quarter ended July 30, 2010.

26 Aug 2010

Researchers identify specific gene responsible for Kuf's disease

A North Carolina State University researcher has helped to locate and identify a gene responsible for a fatal neurodegenerative disease that affects American Staffordshire terriers. This same gene may be responsible for a similar rare, fatal disease in humans. Its discovery will lead to improved screening and diagnosis of the disease in dogs and is the first step in working toward a cure for both canines and humans.

25 Aug 2010

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Research in recent years has shown that the brain tries to counteract seizures. One of the ways it does this is by increasing levels of a protein-like molecule called neuropeptide Y and the expression of certain receptors for it.

25 Aug 2010

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.

25 Aug 2010

Cyberonics enters agreement with NeuroVista for epilepsy technology development program

Cyberonics, Inc. today announced that it has entered into additional agreements with NeuroVista Corporation in the field of EEG-based seizure detection to build on its position as the leader in medical devices for epilepsy.

25 Aug 2010

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.

24 Aug 2010

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended June 30, 2010. The Company reported a net loss of $4,623,000, or $0.10 per share, compared to a net loss of $426,000, or $0.01 per share, for the three months ended June 30, 2009. The third quarter 2010 results include a non-cash financing and change in valuation charge of $3,856,000. Loss from operations for the three months ended June 30, 2010 were $750,000 compared to $445,000 for the three months ended June 30, 2009.

16 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

The NIH has granted a University of Texas at Dallas researcher and a university-affiliated biomedical firm $1.7 million to investigate whether nerve stimulation offers a long-term cure for tinnitus.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Catalyst announces $1.5 million registered direct offering

Catalyst Pharmaceutical Partners, Inc. today announced that it has entered into definitive agreements to sell 1,351,352 shares of its common stock at a price per share of $1.11 pursuant to a registered direct offering to two large mutual funds, representing gross proceeds of $1.5 million.

7 Aug 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Researchers recommend traumatic brain injury reclassification for additional funding

Researchers find two high-fat diets reduce absence epilepsy in children

NSW bed sore death could have been prevented: Coroner

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

Cyberonics reports 16% increase in net sales for first quarter 2011

Researchers identify specific gene responsible for Kuf's disease

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

Cyberonics enters agreement with NeuroVista for epilepsy technology development program

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Catalyst second-quarter net loss decreases to $1,328,541

Neurologix second-quarter net loss increases to $4.5 million

FDA advisory committee votes in favor of Ezogabine

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Catalyst announces $1.5 million registered direct offering

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Epilepsy News and Research

Latest Epilepsy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in